MedPath

The AT-REBOA Target Trial

Completed
Conditions
Hemorrhage
Shock, Traumatic
Cardiac Arrest Due to Trauma
Polytrauma
Registration Number
NCT06312436
Lead Sponsor
Medical University of Graz
Brief Summary

Temporary aortic occlusion can limit haemorrhage, can help to maintain perfusion to the heart and brain, and may be associated with improved survival. Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) potentially provides a relatively quick means of achieving this temporary control.

In the past years, studies have tried to evaluate the benefit for this method with conflicting results. The previous UK-REBOA trial has not found any benefit in the intervention group and has even hinted at possible harm caused by the intervention. A major limitation of this study is the low number of interventions performed in participating trauma centres and the associated potentially insufficient experience with REBOA.

The aim of this study is to evaluate the effectiveness of REBOA in a setting with already experienced providers.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
44
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
30-day in-hospital mortality30 days
Secondary Outcome Measures
NameTimeMethod
Time to damage control procedureduring resuscitation phase within 3 hours

operation or angioembolisation

24-hour mortality24 hours
3-hour mortality3 hours
6-hour mortality6 hours
Blood product use48 hours

amount of packed red blood cells, amount of fresh frozen plasma, amount of thrombocyte concentrates

Rate of complicationswithin 6 months

acute kidney injury °III, use of renal replacement therapy, arterial thrombosis or embolism, limb ischaemia, vascular injury, compartment syndrome requiring fasciotomy

Intensive Care Unit length of staywithin 6 months

days

Use of whole body computed tomographyduring resuscitation care phase within 3 hours
damage control procedure performedduring resuscitation phase within 3 hours

operation or angioembolisation

Hospital length of staywithin 6 months

days

Cause of deathwithin 6 months
90-day mortality90 days

Trial Locations

Locations (2)

University Medical Centre Graz

🇦🇹

Graz, Styria, Austria

Center for Medical Data Science

🇦🇹

Vienna, Austria

University Medical Centre Graz
🇦🇹Graz, Styria, Austria

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.